{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-031185","form_type":"8-K","ticker":null,"cik":"0001042074","company_name":"CymaBay Therapeutics, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.201276+00:00","generated_at":"2026-06-06T04:07:16.302987+00:00","sec_items":["1.01","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Gilead to acquire CymaBay for $32.50/sh ($4.3B); seladelpar PBC drug with priority review","bullets":["All-cash tender at $32.50/share, a 27% premium to Feb. 9 close; equity value ~$4.3B.","Seladelpar (PPARδ agonist) for primary biliary cholangitis has FDA priority review; PDUFA Aug. 14, 2024.","Phase 3 RESPONSE trial: 61.7% biochemical response vs 20% placebo; 25% ALP normalization vs 0%.","Closing expected Q1 2024, subject to HSR and minimum tender of majority of shares.","Termination fee of $151.6M payable by CymaBay under certain circumstances."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-031185","json":"https://secwatch.observer/filing/0001193125-24-031185.json","markdown":"https://secwatch.observer/filing/0001193125-24-031185.md","text":"https://secwatch.observer/filing/0001193125-24-031185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/d791540d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:07:16.302987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcea977527f5d0f125fb78b9232b0a74884c8dd8","claim":"CymaBay Therapeutics, Inc.: Added new Article XV to Bylaws establishing exclusive forum provisions for certain legal actions, including federal district courts for Securities Act and Exchange Act claims (effective 2024-02-11).","evidence_excerpt":"On February 11, 2024, the Board adopted an amendment (the “ Amendment ”) to the Company’s bylaws (as may be amended from time to time, the “ Bylaws ”), which became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-02-11"}],"fact_type":"governance_change"},{"claim_id":"bf251d06178d1ac01e9e968f7e6e27071560135f","claim":"CymaBay Therapeutics, Inc. entered into Agreement and Plan of Merger with Gilead Sciences, Inc. (effective 2024-02-11).","evidence_excerpt":"On February 11, 2024, CymaBay Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Gilead Sciences, Inc., a Delaware corporation (“ Parent ”), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1042074/000119312524031185/0001193125-24-031185-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Effective","value":"2024-02-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}